The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Treatment of bleeding complications in patients on anticoagulant therapy
Abstract
Anticoagulant therapy is often refrained from out of fear of hemorrhagic complications. The most frequent type of major bleeding is gastrointestinal, but intracranial hemorrhage has the worst prognosis. Management of these complications in patients on anticoagulants should follow the same routines as for nonanticoagulated patients, as described here with the previously mentioned bleeds as examples. In addition, for life-threatening or massive hemorrhages, reversal of the anticoagulant effect is also crucial. Adequate reversal requires information on which anticoagulant the patient has taken and when the last dose was ingested. Laboratory data can be of some help, but not for all anticoagulants in the emergency setting. This is reviewed here for the different types of anticoagulants: vitamin K antagonists, heparins, fondaparinux, thrombin inhibitors and factor Xa inhibitors. Specific antidotes for the latter are becoming available, but supportive care and nonspecific support for hemostasis with antifibrinolytic agents or prothrombin complex concentrates, which are widely available, should be kept in mind.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Anticoagulant therapy is very effective at preventing recurrent VTE but is associated with an increased frequency of bleeding complications.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [15]
In the citing paper
“Major bleeding events may occur in ; 1% to 3% of patients on VKAs each year, compared to an ; 30% lower relative risk for major bleeding with DOACs. 15”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [15]
In the citing paper
“Anticoagulant therapy is very effective at preventing recurrent VTE but is associated with an increased frequency of bleeding complications.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [15]
In the citing paper
“Major bleeding events may occur in ; 1% to 3% of patients on VKAs each year, compared to an ; 30% lower relative risk for major bleeding with DOACs. 15”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [15]
Citations
Cites
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Self-citationMehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309023291001 · Cited by 4,055
Hemphill, J. C., Greenberg, S. M., Anderson, C. S., Becker, K., Bendok, B. R., Cushman, M., Fung, G. L., Goldstein, J. N., Macdonald, R. L., Mitchell, P. H., et al. (2015) · Stroke · doi:10.1161/str.0000000000000069 · Cited by 3,994
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Self-citationChesebro, J. H., Knatterud, G., Roberts, R., Borer, J., Cohen, L. S., Dalen, J., Dodge, H. T., Francis, C. K., Hillis, D., & Ludbrook, P. (1987) · Circulation · doi:10.1161/01.cir.76.1.142 · Cited by 2,244
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
Kaatz, S., Ahmad, D., Spyropoulos, A. C., & Schulman, S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13140 · Cited by 1,419
Self-citation
Research works printed but not linked: 3
- Connolly, Interim Report on the ANNEXA-4 Study: andexanet for reversal of anticoagulation in factor Xa - associated acute major bleeding
- Piran, 2018, Reversal of direct factor Xa inhibitor-associated major bleeding with four-factor prothrombin complex concentrate: a systematic review and meta-analysis, Res Pract Thromb Haemost, 2, PB449
- UPMC System Pharmacy and Therapeutic Committee Formulary Review. Prothrombin complex concentrate (human) (Kcentra®, CSL Behring LLC). Available at: https://emcrit.org/wp-content/uploads/2013/12/Kcentra_4FPCC_SPT.pdf. Accessed 20 December 2018.
Cited by
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
“Remarks: Factors, such as a requirement for lead-in parenteral anticoagulation, once- vs twice-daily dosing, and out-of-pocket cost may drive the selection of specific DOACs.”
BackgroundInfluentialSelf-citationBallestri, S., Romagnoli, E., Arioli, D., Coluccio, V., Marrazzo, A., Athanasiou, A., Girolamo, M. D., Cappi, C., Marietta, M., & Capitelli, M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02333-9 · Cited by 146
Definition of major bleeding: Prognostic classification
Franco, L., Becattini, C., Beyer‐Westendorf, J., Vanni, S., Nitti, C., Re, R., Manina, G., Pomero, F., Cappelli, R., Conti, A., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15048 · Cited by 96
“AF VTE 855 (79) 118 (11) 392 (76) 61 (12) 463 (83) 57 (10)”
Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage
Kuramatsu, J. B., Sembill, J. A., & Huttner, H. B. (2019) · Critical Care · doi:10.1186/s13054-019-2492-8 · Cited by 79
Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications
Ma, Z., Yang, Y., Huang, Y., & Lui, K. O. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.11.010 · Cited by 75
Metadata
- Authors
- Piran, S., & Schulman, S.
- Affiliations
- Thrombosis and Atherosclerosis Research Institute (CA)
- Sechenov University (RU)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2019-01-31
- Volume
- 133
- Issue
- 5
- Pages
- 425-435
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2904680572
- Cited by
- 108
- References
- 75
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 17 · 2023: 18 · 2022: 24 · 2021: 12 · 2020: 10 · 2019: 4
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- anticoagulant-induced bleeding, bleeding complications, anticoagulant reversal, vitamin K antagonists, heparin, fondaparinux, thrombin inhibitors, factor Xa inhibitors, intracranial hemorrhage, gastrointestinal bleeding, antifibrinolytic agents, prothrombin complex concentrate, emergency management
- MeSH terms
- Anticoagulants, Antithrombins, Hemorrhage, Heparin, Humans, Vitamin K, Disease Management, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of bleeding complications in patients on anticoagulant therapy. https://app.cochat.ai/papers/10.1182/blood-2018-06-820746
- The paper
- Piran, S., & Schulman, S. (2019). Treatment of bleeding complications in patients on anticoagulant therapy. Blood. https://doi.org/10.1182/blood-2018-06-820746
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.